(Q35047919)

6 August 2017

1 reference

title

Management of primary osteoporosis (English)

1 reference

6 August 2017

0 references

J J Body

1

1 reference

6 August 2017

publication date

1 September 2002

1 reference

6 August 2017

1 reference

6 August 2017

volume

57

1 reference

6 August 2017

issue

5

1 reference

6 August 2017

page(s)

277-283

1 reference

World-wide projections for hip fracture

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1179%2FACB.2002.054

Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2002.054

21 January 2018

Calcium and osteoporosis

1 reference

https://api.crossref.org/works/10.1179%2FACB.2002.054

Vitamin D3 and calcium to prevent hip fractures in elderly women

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2002.054

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2002.054

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2002.054

Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2002.054

Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2002.054

Cyclical pamidronate infusions in postmenopausal osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2002.054

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2002.054

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2002.054

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2002.054

Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2002.054

Risedronate for the prevention and treatment of postmenopausal osteoporosis: results from recent clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2002.054

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2002.054

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2002.054

Intravenous zoledronic acid in postmenopausal women with low bone mineral density

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2002.054

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2002.054

A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2002.054

21 January 2018

Identifiers

DOI

10.1179/ACB.2002.054

1 reference

6 August 2017

1 reference